A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.
Also called NCT06199505
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 153 participants
- Registry
-
NCT06199505
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06199505. Randomized; no masking; primary purpose treatment. Start 2023-11-21 (actual); primary completion 2024-06-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- GZR101
- Intervention (Drug)
- insulin degledec/insulin aspart
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
Record details
- Record id
cardio:ct-nct06199505- Content hash
4d4cdad1d7f40e2856c63c6c42cca9db81609fe57149e06972f71d7a4c8c7d64